| |
| |
| |
| |
| |
Improving Early Prostate Cancer Diagnosis
Egenix has developed a blood test for the early diagnosis of prostate cancer. The Company's innovative approach to measurement of complex PSA (prostate specific antigen) will substantially improve the specificity of screening for the early diagnosis of prostate cancer.
Our diagnostic, PACT, is a novel screening test for prostate cancer. Egenix' test is a sandwich ELISA immunoassay. Data from the first clinical samples tested in two separate clinical evaluations showed a specificity of greater than 65% at a sensitivity of 90%. At this threshold, unnecessary biopsies (versus PSA) could be reduced by two-thirds.
Egenix’ complex PSA test more than doubles the specificity of current versions of the complex PSA test and improves the accuracy of testing for early diagnosis of prostate cancer.